This work is licensed under the Creative Commons Attribution 4.0 International License.
Hailu HE, Mondul AM, Rozek LS, Geleta T. Descriptive epidemiology of breast and gynecological cancers among patients attending Saint Paul's Hospital Millennium Medical College, Ethiopia. PLoS One 2020; 15: e0230625. doi: 10.1371/journal.pone.0230625HailuHEMondulAMRozekLSGeletaTDescriptive epidemiology of breast and gynecological cancers among patients attending Saint Paul's Hospital Millennium Medical College, Ethiopia202015e023062510.1371/journal.pone.0230625Open DOISearch in Google Scholar
Sinno AK, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, et al. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: a Society of Gynecologic Oncology (SGO) clinical practice statement: this practice statement has been endorsed by the North American Menopause Society. Gynecol Oncol 2020; 157: 303–6. doi: 10.1016/j.ygyno.2020.01.035SinnoAKPinkertonJFebbraroTJonesNKhannaNTemkinSHormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: a Society of Gynecologic Oncology (SGO) clinical practice statement: this practice statement has been endorsed by the North American Menopause Society2020157303610.1016/j.ygyno.2020.01.035Open DOISearch in Google Scholar
Mension E, Alonso I, Castelo-Branco C. Genitourinary syndrome of menopause: current treatment options in breast cancer survivors - systematic review. Maturitas 2021; 143: 47–58. doi: 10.1016/j.maturitas.2020.08.010MensionEAlonsoICastelo-BrancoCGenitourinary syndrome of menopause: current treatment options in breast cancer survivors - systematic review2021143475810.1016/j.maturitas.2020.08.010Open DOISearch in Google Scholar
Portman DJ, Gass MLS; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014; 21: 1063–8. doi:10.1097/GME.0000000000000329PortmanDJGassMLSVulvovaginal Atrophy Terminology Consensus Conference PanelGenitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society2014211063810.1097/GME.0000000000000329Open DOISearch in Google Scholar
Farrell Am E. Genitourinary syndrome of menopause. Aust Fam Physician 2017; 46: 481–4. PMID: 28697291Farrell AmEGenitourinary syndrome of menopause201746481428697291Search in Google Scholar
The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause 2020; 27: 976–92. doi: 10.1097/GME.0000000000001609The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society2020279769210.1097/GME.0000000000001609Open DOISearch in Google Scholar
Aerts L, Enzlin P, Verhaeghe J, Poppe W, Vergote I, Amant F. Sexual functioning in women after surgical treatment for endometrial cancer: a prospective controlled study. J Sex Med 2015; 12: 198–209. doi: 10.1111/jsm.12764AertsLEnzlinPVerhaegheJPoppeWVergoteIAmantFSexual functioning in women after surgical treatment for endometrial cancer: a prospective controlled study20151219820910.1111/jsm.12764Open DOISearch in Google Scholar
Aerts L, Enzlin P, Verhaeghe J, Poppe W, Vergote I, Amant F. Long-term sexual functioning in women after surgical treatment of cervical cancer stages IA to IB: a prospective controlled study. Int J Gynecol Cancer 2014; 24: 1527–34. doi: 10.1097/IGC.0000000000000236AertsLEnzlinPVerhaegheJPoppeWVergoteIAmantFLong-term sexual functioning in women after surgical treatment of cervical cancer stages IA to IB: a prospective controlled study20142415273410.1097/IGC.0000000000000236Open DOISearch in Google Scholar
Chan JL, Letourneau J, Salem W, Cil AP, Chan SW, Chen LM, et al. Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery. Gynecol Oncol 2015; 139: 141–7. doi: 10.1016/j.ygyno.2015.07.105ChanJLLetourneauJSalemWCilAPChanSWChenLMSexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery2015139141710.1016/j.ygyno.2015.07.105Open DOISearch in Google Scholar
Tramacere F, Lancellotta V, Casà C, Fionda B, Cornacchione P, Mazzarella C, et al. Assessment of sexual dysfunction in cervical cancer patients after different treatment modality: a systematic review. Med Kaunas Lith 2022; 58: 1223. doi: 10.3390/medicina58091223TramacereFLancellottaVCasàCFiondaBCornacchionePMazzarellaCAssessment of sexual dysfunction in cervical cancer patients after different treatment modality: a systematic review202258122310.3390/medicina58091223Open DOISearch in Google Scholar
Kirchheiner K, Smet S, Jürgenliemk-Schulz IM, Haie-Meder C, Chargari C, Lindegaard JC, et al. Impact of vaginal symptoms and hormonal replacement therapy on sexual outcomes after definitive chemoradiotherapy in patients with locally advanced cervical cancer: results from the EMBRACE-I study. Int J Radiat Oncol Biol Phys 2022; 112: 400–13. doi: 10.1016/j.ijrobp.2021.08.036KirchheinerKSmetSJürgenliemk-SchulzIMHaie-MederCChargariCLindegaardJCImpact of vaginal symptoms and hormonal replacement therapy on sexual outcomes after definitive chemoradiotherapy in patients with locally advanced cervical cancer: results from the EMBRACE-I study20221124001310.1016/j.ijrobp.2021.08.036Open DOISearch in Google Scholar
Gandhi J, Chen A, Dagur G, Y, Smith N, Cali B, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol 2016; 215: 704–11. doi: 10.1016/j.ajog.2016.07.045GandhiJChenADagurG YSmithNCaliBGenitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management20162157041110.1016/j.ajog.2016.07.045Open DOISearch in Google Scholar
Brennan A, Brennan D, Rees M, Hickey M. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer. Int J Gynecol Cancer 2021; 31: 352–9. doi: 10.1136/ijgc-2020-002032BrennanABrennanDReesMHickeyMManagement of menopausal symptoms and ovarian function preservation in women with gynecological cancer202131352910.1136/ijgc-2020-002032Open DOISearch in Google Scholar
Laios A, Otify M, Papadopoulou A, Gallos ID, Ind T. Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis. BMC Womens Health 2022; 22: 305. doi: 10.1186/s12905-022-01887-8LaiosAOtifyMPapadopoulouAGallosIDIndTOutcomes of ovarian transposition in cervical cancer; an updated meta-analysis20222230510.1186/s12905-022-01887-8Open DOISearch in Google Scholar
Bober SL, Reese JB, Barbera L, Bradford A, PhD, Carpenter KM, Goldfarb S, et al. How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer. Curr Opin Support Palliat Care 2016; 10: 44–54. doi: 10.1097/SPC.0000000000000186BoberSLReeseJBBarberaLBradfordAPhDCarpenterKMGoldfarbSHow to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer201610445410.1097/SPC.0000000000000186Open DOISearch in Google Scholar
Erekson EA, Yip SO, Wedderburn TS, Martin DK, Li FY, Choi, JN, et al. The vulvovaginal symptoms questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause 2013; 20: 973–9. doi: 10.1097/GME.0b013e318282600bEreksonEAYipSOWedderburnTSMartinDKLiFYChoiJNThe vulvovaginal symptoms questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women201320973910.1097/GME.0b013e318282600bOpen DOISearch in Google Scholar
Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause 2018; 25: 596–608. doi: 10.1097/GME.0000000000001121FaubionSSLarkinLCStuenkelCABachmannGAChismLAKaganRManagement of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health20182559660810.1097/GME.0000000000001121Open DOISearch in Google Scholar
Angelou K, Grigoriadis T, Diakosavvas M, Zacharakis D, Athanasiou S. The genitourinary syndrome of menopause: an overview of the recent data. Cureus 2020; 12: e7586. doi: 10.7759/cureus.7586AngelouKGrigoriadisTDiakosavvasMZacharakisDAthanasiouSThe genitourinary syndrome of menopause: an overview of the recent data202012e758610.7759/cureus.7586Open DOISearch in Google Scholar
Matos SR de L, Lucas Rocha Cunha M, Podgaec S, Weltman E, Yamazaki Centrone AF, Cintra Nunes Mafra AC. Consensus for vaginal stenosis prevention in patients submitted to pelvic radiotherapy. PloS One 2019; 14: e0221054. doi: 10.1371/journal.pone.0221054MatosSR de LLucas Rocha CunhaMPodgaecSWeltmanEYamazaki CentroneAFCintra Nunes MafraACConsensus for vaginal stenosis prevention in patients submitted to pelvic radiotherapy201914e022105410.1371/journal.pone.0221054Open DOISearch in Google Scholar
Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric J Int Menopause Soc 2018; 21: 167–73. doi: 10.1080/13697137.2017.1421921MoralEDelgadoJLCarmonaFCaballeroBGuillánCGonzálezPMGenitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study2018211677310.1080/13697137.2017.1421921Open DOISearch in Google Scholar
George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors: letrozole in uterine leiomyosarcoma. Cancer 2014; 120: 738–43. doi: 10.1002/cncr.28476GeorgeSFengYManolaJNucciMRButrynskiJEMorganJAPhase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors: letrozole in uterine leiomyosarcoma20141207384310.1002/cncr.28476Open DOISearch in Google Scholar
Didar H, Farzaneh F, Najafiarab H, Kosar Namakin K, Gohari K, Sheidaei A, et al. Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis. Curr Med Res Opin 2023; 39: 901–10. doi: 10.1080/03007995.2023.2208488DidarHFarzanehFNajafiarabHKosar NamakinKGohariKSheidaeiAClear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis2023399011010.1080/03007995.2023.2208488Open DOISearch in Google Scholar
de Hullu JA, Pras E, Hollema H, van dr Zee AGJ, Bogchelman DH, Mourits MJE. Presentations of endometrial activity after curative radiotherapy for cervical cancer. Maturitas 2005; 51: 172–6. doi: 10.1016/j.maturitas.2004.07.005de HulluJAPrasEHollemaHvan dr ZeeAGJBogchelmanDHMouritsMJEPresentations of endometrial activity after curative radiotherapy for cervical cancer200551172610.1016/j.maturitas.2004.07.005Open DOISearch in Google Scholar
Mlinarič M, Arko D, Barbič M, Alenka Pretnar-Darovec A, Darovec J, Geršak K, et al. [Expert recommendations on menopausal medicine]. [Slovenian]. Ljubljana: Slovenian Menopause Association. Medical Association of Slovenia; 2021.MlinaričMArkoDBarbičMAlenka Pretnar-DarovecADarovecJGeršakKLjubljanaSlovenian Menopause Association. Medical Association of Slovenia2021Search in Google Scholar
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JAV, et al. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100: 3975–4011. doi: 10.1210/jc.2015-2236StuenkelCADavisSRGompelALumsdenMAMuradMHPinkertonJAVTreatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline20151003975401110.1210/jc.2015-2236Open DOISearch in Google Scholar
Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8(Suppl 1): 3–63. doi: 10.1080/13697130500148875KuhlHPharmacology of estrogens and progestogens: influence of different routes of administration20058Suppl 136310.1080/13697130500148875Open DOISearch in Google Scholar
Crean-Tate KK, Faubion SS, Pederson HJ, Vencill JA, Batur P. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. Am J Obstet Gynecol 2020; 222: 103–13. doi: 10.1016/j.ajog.2019.08.043Crean-TateKKFaubionSSPedersonHJVencillJABaturPManagement of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy20202221031310.1016/j.ajog.2019.08.043Open DOISearch in Google Scholar
La Rosa VL, Ciebiera M, Lin LT, Fan S, Butticè S, Sathyapalan T, et al. Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function. Prz Menopauzalny 2019; 18: 116–122. doi: 10.5114/pm.2019.86836La RosaVLCiebieraMLinLTFanSButticèSSathyapalanTTreatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function20191811612210.5114/pm.2019.86836Open DOISearch in Google Scholar
Santen RJ, Pinkerton JV, Conaway M, Ropka M, Wisniewski L, Demers L, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002; 9: 179–87. doi: 10.1097/00042192-200205000-00006SantenRJPinkertonJVConawayMRopkaMWisniewskiLDemersLTreatment of urogenital atrophy with low-dose estradiol: preliminary results200291798710.1097/00042192-200205000-00006Open DOISearch in Google Scholar
Chambers LM, Herrmann A, Michener CM, Ferrando CA, Ricci S. Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma. Int J Gynecol Cancer 2020; 30: 515–24. doi: 10.1136/ijgc-2019-001034ChambersLMHerrmannAMichenerCMFerrandoCARicciSVaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma2020305152410.1136/ijgc-2019-001034Open DOISearch in Google Scholar
Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Ggnecologic Oncology Group study. J Clin Oncol 2006; 24: 587–92. doi: 10.1200/JCO.2005.02.8464BarakatRRBundyBNSpirtosNMBellJMannelRSRandomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Ggnecologic Oncology Group study2006245879210.1200/JCO.2005.02.8464Open DOISearch in Google Scholar
Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 2014; 50: 1628–37. doi: 10.1016/j.ejca.2014.03.006ShimSHLeeSJKimSNEffects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis20145016283710.1016/j.ejca.2014.03.006Open DOISearch in Google Scholar
Li D, Ding C, Qiu L. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol 2015; 139: 355–62. doi: 10.1016/j.ygyno.2015.07.109LiDDingCQiuLPostoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis20151393556210.1016/j.ygyno.2015.07.109Open DOISearch in Google Scholar
Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2012; 125: 661–6. doi: 10.1016/j.ygyno.2012.02.037GershensonDMSunCCIyerRBMalpicaALKavanaghJJBodurkaDCHormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum2012125661610.1016/j.ygyno.2012.02.037Open DOISearch in Google Scholar
Power L, Lefas G, Lambert P, Kim D, Evaniuk D, Lotocki R, et al. Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival. Obstet Gynecol 2016; 126: 837–47. doi: 10.1097/AOG.0000000000001396PowerLLefasGLambertPKimDEvaniukDLotockiRHormone use after nonserous epithelial ovarian cancer: overall and disease-free survival20161268374710.1097/AOG.0000000000001396Open DOISearch in Google Scholar
Ploch, E. Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment. Gynecol Oncol 1987; 26: 169–77. doi: 10.1016/0090-8258(87)90270-8PlochEHormonal Replacement Therapy in Patients after Cervical Cancer Treatment1987261697710.1016/0090-8258(87)90270-8Open DOISearch in Google Scholar
Rizzuto I, Oehler MK, Lalondrelle S. Sexual and psychosexual consequences of treatment for gynaecological cancers. Clin Oncol (R Coll Radiol) 2021; 33: 602–7. doi: 10.1016/j.clon.2021.07.003RizzutoIOehlerMKLalondrelleSSexual and psychosexual consequences of treatment for gynaecological cancers202133602710.1016/j.clon.2021.07.003Open DOISearch in Google Scholar
Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med 2014; 11: 487–97. doi: 10.1111/jsm.12377CuiYZongHYanHLiNZhangYThe efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis2014114879710.1111/jsm.12377Open DOISearch in Google Scholar
Simon JA, Lin VH, Radovich C, Bachmann GA; Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013; 20: 418–27. doi: 10.1097/gme.0b013e31826d36baSimonJALinVHRadovichCBachmannGAOspemifene Study GroupOne-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus2013204182710.1097/gme.0b013e31826d36baOpen DOISearch in Google Scholar
Simon J, Portman D, Mabey RG; Ospemifene Study Group. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas 2014; 77: 274–81. doi: 10.1016/j.maturitas.2013.12.005SimonJPortmanDMabeyRGOspemifene Study GroupLong-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women2014772748110.1016/j.maturitas.2013.12.005Open DOISearch in Google Scholar
Barton DL, Shuster LT, Dockter T, Atherton PJ, Thielen J, Birrell SN, et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer 2018; 26: 1335–43. doi: 10.1007/s00520-017-3960-BartonDLShusterLTDockterTAthertonPJThielenJBirrellSNSystemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)20182613354310.1007/s00520-017-3960-Open DOISearch in Google Scholar
Labrie F, Archer DF, Koltun W, Andrée Vachon, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016; 23: 243–56. doi: 10.1097/GME.0000000000000571LabrieFArcherDFKoltunWVachonAndréeYoungDFrenetteLEfficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause2016232435610.1097/GME.0000000000000571Open DOISearch in Google Scholar
Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2015; 33: 3394–400. doi: 10.1200/JCO.2014.60.7366GoetschMFLimJYCaugheyABA practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial201533339440010.1200/JCO.2014.60.7366Open DOISearch in Google Scholar
Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 2016; 19: 151–61. doi: 10.3109/13697137.2015.1124259EdwardsDPanayNTreating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?2016191516110.3109/13697137.2015.1124259Open DOISearch in Google Scholar
Karamanidis D, Tamiolakis D, Koutsougeras G, Tripsanas CH, Retzos K, Karidis S, et al. Cigarette smoking and the degree of maturation of the vaginal squamous epithelium in postmenopausal women. Clin Exp Obstet Gynecol 2001; 28: 274–76. PMID: 11838758KaramanidisDTamiolakisDKoutsougerasGTripsanasCHRetzosKKaridisSCigarette smoking and the degree of maturation of the vaginal squamous epithelium in postmenopausal women2001282747611838758Search in Google Scholar
Daily JW, Ko BS, Ryuk J, Liu M, Zhang W, Park S. Equol decreases hot flashes in postmenopausal women: a systematic review and meta-analysis of randomized clinical trials. J Med Food 2019; 22: 127–39. doi: 10.1089/jmf.2018.4265DailyJWKoBSRyukJLiuMZhangWParkSEquol decreases hot flashes in postmenopausal women: a systematic review and meta-analysis of randomized clinical trials2019221273910.1089/jmf.2018.4265Open DOISearch in Google Scholar
Caruso S, Cianci S, Fava V, Rapisarda AMC, Cutello S, Cianci A. Vaginal health of postmenopausal women on nutraceutical containing equol. Menopause 2018; 25: 430–35. doi: 10.1097/GME.0000000000001061CarusoSCianciSFavaVRapisardaAMCCutelloSCianciAVaginal health of postmenopausal women on nutraceutical containing equol2018254303510.1097/GME.0000000000001061Open DOISearch in Google Scholar
Mortensen OE, Christensen SE, Løkkegaard E. The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: a state-of-the-art review. Acta Obstet Gynecol Scand 2022; 101: 657–92. doi: 10.1111/aogs.14353MortensenOEChristensenSELøkkegaardEThe evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: a state-of-the-art review20221016579210.1111/aogs.14353Open DOISearch in Google Scholar
Perrone AM, Tesei M, Ferioli M, De Terlizzi F, Gatta AND, Boussedra S, et al. Results of a phase I-II study on laser therapy for vaginal side effects after radiotherapy for cancer of uterine cervix or endometrium. Cancers 2020; 12: 1639. doi: 10.3390/cancers12061639PerroneAMTeseiMFerioliMDe TerlizziFGattaANDBoussedraSResults of a phase I-II study on laser therapy for vaginal side effects after radiotherapy for cancer of uterine cervix or endometrium202012163910.3390/cancers12061639Open DOISearch in Google Scholar
Charatsi D, Vanakara P, Evaggelopoulou E, Simopoulou F, Korfias D, Daponte A, et al. Vaginal dilator use to promote sexual wellbeing after radiotherapy in gynecological cancer survivors. Medicine 2022; 101: e28705. doi: 10.1097/MD.0000000000028705CharatsiDVanakaraPEvaggelopoulouESimopoulouFKorfiasDDaponteAVaginal dilator use to promote sexual wellbeing after radiotherapy in gynecological cancer survivors2022101e2870510.1097/MD.0000000000028705Open DOISearch in Google Scholar
Martins J, Vaz AF, Grion RC, Costa-Paiva L, Baccaro LF. Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial. BMC Cancer. 2021; 21: 682. doi: 10.1186/s12885-021-08274-wMartinsJVazAFGrionRCCosta-PaivaLBaccaroLFTopical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial20212168210.1186/s12885-021-08274-wOpen DOISearch in Google Scholar